TP Miller

4.0k total citations · 1 hit paper
28 papers, 3.3k citations indexed

About

TP Miller is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, TP Miller has authored 28 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pathology and Forensic Medicine, 17 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in TP Miller's work include Lymphoma Diagnosis and Treatment (20 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Drug Transport and Resistance Mechanisms (4 papers). TP Miller is often cited by papers focused on Lymphoma Diagnosis and Treatment (20 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Drug Transport and Resistance Mechanisms (4 papers). TP Miller collaborates with scholars based in United States and Malaysia. TP Miller's co-authors include TM Grogan, CM Spier, Thomas M. Grogan, William S. Dalton, BN Nathwani, SE Jones, Catherine Spier, Steve Dahlberg, Lippman Sm and Charles W. Taylor and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

TP Miller

28 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

1989 478 citations William S. Dalton, Thomas M. Grogan et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by TP Miller

Since Specialization

Citations

This map shows the geographic impact of TP Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by TP Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites TP Miller more than expected).

Fields of papers citing papers by TP Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by TP Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by TP Miller. The network helps show where TP Miller may publish in the future.

Co-authorship network of co-authors of TP Miller

This figure shows the co-authorship network connecting the top 25 collaborators of TP Miller. A scholar is included among the top collaborators of TP Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with TP Miller. TP Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone 2012 ·Haematologica ·Daniel O. Persky, David Dornan, Bryan Goldman, Rita M. Braziel, R I Fisher, Michael LeBlanc, David G. Maloney, Oliver W. Press, TP Miller, Lisa M. Rimsza	51
2	Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial 1994 ·Blood ·TP Miller, TM Grogan, Steve Dahlberg, CM Spier, RM Braziel, (unknown), Kathryn Foucar, CR Kjeldsberg, Nicolas Lévy, BN Nathwani	204
3	Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial 1994 ·Blood ·TP Miller, TM Grogan, Steve Dahlberg, CM Spier, RM Braziel, (unknown), Kathryn Foucar, CR Kjeldsberg, Nicolas Lévy, BN Nathwani	174
4	Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement [see comments] 1992 ·Blood ·(unknown), CM Spier, (unknown), TP Miller, M Matzner, TM Grogan	181
5	P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. 1991 ·Journal of Clinical Oncology ·TP Miller, Thomas M. Grogan, William S. Dalton, Catherine Spier, R J Scheper, S. E. Salmon	328
6	Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer 1991 ·Blood ·SE Salmon, WS Dalton, TM Grogan, (unknown), (unknown), DJ Roe, TP Miller	195
7	Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. 1991 ·Journal of Clinical Oncology ·Richard T. Silver, Delvyn C. Case, (unknown), TP Miller, Richard S. Stein, John J. Stuart, B. A. Peterson, S E Rivkin, (unknown), (unknown)	45
8	Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer 1991 ·Blood ·SE Salmon, WS Dalton, TM Grogan, (unknown), (unknown), DJ Roe, TP Miller	10
9	Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study. 1990 ·Journal of Clinical Oncology ·Charles W. Taylor, John Crowley, Stephen K. Williamson, TP Miller, (unknown), (unknown), Ronald L. Stephens, Robert B. Livingston	29
10	Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. breakdown → 1989 ·Journal of Clinical Oncology ·William S. Dalton, Thomas M. Grogan, Paul S. Meltzer, Rik J. Scheper, B G M Durie, Charles W. Taylor, TP Miller, S. E. Salmon	478
11	HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. 1988 ·Journal of Clinical Investigation ·TP Miller, Scott M. Lippman, Catherine Spier, Donald J. Slymen, Thomas M. Grogan	82
12	Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67 1988 ·Blood ·TM Grogan, Lippman Sm, CM Spier, (unknown), (unknown), (unknown), L Richter, TP Miller	7
13	Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67 1988 ·Blood ·TM Grogan, Lippman Sm, CM Spier, (unknown), (unknown), (unknown), L Richter, TP Miller	190
14	The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype 1988 ·Blood ·Lippman Sm, TP Miller, CM Spier, (unknown), TM Grogan	84
15	Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. 1987 ·Journal of Clinical Oncology ·Keith A.A. Fox, Scott M. Lippman, J. Robert Cassady, Robert S. Heusinkveld, TP Miller	68
16	What should be the morphologic criteria for the subdivision of follicular lymphomas? 1986 ·Blood ·BN Nathwani, Metter Ge, TP Miller, (unknown), (unknown), (unknown), CR Kjeldsberg, (unknown), CD Winberg, (unknown)	3
17	Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. 1986 ·Journal of Clinical Oncology ·Dennis O. Dixon, Barbara A. Neilan, Siân Jones, David A. Lipschitz, TP Miller, P Grozea, Henry E. Wilson	300
18	Initial chemotherapy for clinically localized lymphomas of unfavorable histology 1983 ·Blood ·TP Miller, SE Jones	162
19	Treatment of small cell lung cancer with VP-16, vincristine, doxorubicin (Adriamycin), cyclophosphamide (EVAC), and high-dose chest radiotherapy. 1983 ·Journal of Clinical Oncology ·Gary E. Goodman, TP Miller, (unknown), (unknown), (unknown)	26
20	Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with advanced Hodgkin's disease: a Southwest Oncology Group Phase II Study. 1983 ·PubMed ·TP Miller, Stephen E. Jones, John M. Rainey	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact